Form 4: Corcept Therapeutics Director David Mahoney Exercises Options and Sells Shares

David Mahoney, a director at Corcept Therapeutics, exercised stock options and sold shares on May 16, 2025, according to a Form 4 filing with the SEC.

Summary

• On May 16, 2025, David L. Mahoney, a director of Corcept Therapeutics, exercised stock options to acquire 30,000 shares of common stock at a price of $6.55 per share.
• Simultaneously, Mahoney sold 23,829 shares at a weighted average price of $74.1723, with prices ranging from $73.54 to $74.525 per share.
• He also sold 3,523 shares at a weighted average price of $74.6525, with prices ranging from $74.54 to $74.80 per share.
• 2,648 shares were withheld to cover the exercise price liability from the option exercise.
• Following these transactions, Mahoney directly owns 3,523 shares and indirectly owns 1,212,614 shares through the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust and 46,147 shares through The Black Dog Private Foundation.
• The stock options were fully exercisable and set to expire on June 18, 2025.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing insider transactions. It doesn't convey any explicit positive or negative sentiment about the company's performance or future prospects.

Industry Context

This filing reflects routine transactions by a company insider and is typical for executives holding stock options. It doesn't necessarily indicate a change in the company's outlook but provides transparency into insider activity.

Comparison to Industry Standards

• Insider transactions are common across publicly traded companies, especially those with stock-based compensation plans.
• The sale of shares after exercising options is a typical strategy for executives to realize gains and manage their personal finances.
• Comparing Mahoney's transactions to those of other directors in similar pharmaceutical companies would provide a better benchmark, but that data isn't available in this document.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• The impact on other stakeholders (employees, customers, suppliers, creditors) is likely negligible.

Key Dates

Keywords

Form 4, Corcept Therapeutics, CORT, David Mahoney, Stock Options, Share Sale, Director, SEC Filing